Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 976-979

  Lourenco J J ^a,b   Maia, R C ^a   Scheiner, M A M ^a   Vasconcelos, F C ^a   Moreira, M A M ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Acute myeloid leukemia; MDR1; Multidrug resistance; P glycoprotein; Pgp activity; Pgp expression; SNPs

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE ACTIVITY; DISEASE ASSOCIATION; FLOW CYTOMETRY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VARIATION (GENETICS);

EID: 40749132492     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.001     Document Type: Article

References (21)

1. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83 (1991) 708-712
2. Wuchter C., Leonid K., Ruppert V., Schrappe M., Buchner T., Schoch C., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85 (2000) 711-721
3. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
4. Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchal S., Witz F., et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular Daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85 (1995) 2147-2153
5. Ambudkar S.V., Kimchi D.C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
6. Tsimberidou A.M., Paterakis G., Androutsos G., Anagnostopoulos N., Galanopoulos A., Kalmantis T., et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 26 (2002) 143-154
7. Mahadevan D., and List F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation a therapeutic strategies. Blood 104 (2004) 1940-1951
8. Hoffmeyer S., Burk O., Von Richter O., Arnold H.P., Brockmo J.L., Johne A., et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 (2002) 3473-3478
9. Kantharidis P., El-Osta S., Silva M., Lee G., Hu X.F., and Zalcberg J. Regulation of PGP gene expression: emerging concepts. Drug Resist Updat 3 (2000) 99-108
10. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
11. Wang B., Ngoi S., Wang J., Chong S.S., and Lee C.G.L. The promoter region of the PGP gene is largely invariant, but different single nucleotide polymorphism haplotypes affect PGP promoter activity differently in different cell lines. Mol Pharmacol 70 (2006) 267-276
12. Ueda K., Clark D.P., Chen C.J., Roninsonll I.B., Gottesman M.M., and Pastan I. The human multidrug resistance (mdrl) gene. J Biol Chem 262 (1987) 505-508
13. Kioka N., Yamano Y., Komano T., and Ueda K. Heat-shock responsive elements in the induction of the multidrug resistance gene (MDRI). FEBS Lett 301 (1992) 37-40
14. Cornwell M.M., and Smith D.E. SP1 activates the MDRl promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268 (1993) 19505-19511
15. Taniguchi S., Mochida Y., Uchiumi T., Tahira T., Hayashi K., Takagi K., et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (PGP) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2 (2003) 1351-1359
16. Takane H., Kobayashi D., Hirota T., Kigawa J., Terakawa N., Otsubo K., et al. Haplotype-oriented genetic analysis a functional assessment of promoter variants in the PGP (ABCB1) gene. J Pharmacol Exp Ther 311 (2004) 1179-1187
17. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297 (2001) 1137-1143
18. Calado R.T., Falcão R.P., Garcia A.B., Gabellini S.M., Zago M.A., and Franco R.F. Influence of functional PGP gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells hematopoietic stem cells. Haematologica 87 (2002) 564-568
19. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House 1997. Hematol J 1 (2000) 53-66
20. Vasconcelos F.C., Gattass C.R., Rumjanek V.M., and Maia R.C. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs 25 (2007) 525-533
21. Pedersen-Bjergaard J., Christiansen D.H., Desta F., and Andersen M.K. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukaemia. Leukemia 20 (2006) 1943-1949